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Background: A growth in the utilization of high-risk allografts is reflective of a critical national shortage
and the increasing waiting list mortality. Using risk-adjusted models, the aim of the present study was to
determine whether a volume–outcome relationship existed among liver transplants at high risk for
allograft failure.
Methods: From 2002 to 2008, the Scientific Registry of Transplant Recipients (SRTR) database for all
adult deceased donor liver transplants (n = 31 587) was queried. Transplant centres (n = 102) were
categorized by volume into tertiles: low (LVC; 31 cases/year), medium (MVC: 64 cases/year) and high
(HVC: 102 cases/year). Donor risk comparison groups were stratified by quartiles of the Donor Risk Index
(DRI) spectrum: low risk (DRI  1.63), moderate risk (1.64 > DRI > 1.90), high risk (1.91 > DRI > 2.26) and
very high risk (DRI  2.27).
Results: HVC more frequently used higher-risk livers (median DRI: LVC: 1.82, MVC: 1.90, HVC: 1.97;
P < 0.0001) and achieved better risk adjusted allograft survival outcomes compared with LVC (HR: 0.90,
95%CI: 0.85–0.95). For high and very high risk groups, transplantation at a HVC did contribute to
improved graft survival [high risk: hazard ratio (HR): 0.85, 95% confidence interval (CI): 0.76–0.96; Very
High Risk: HR: 0.88, 95%CI: 0.78–0.99].
Conclusion: While DRI remains an important aspect of allograft survival prediction models, liver trans-
plantation at a HVC appears to result in improved allograft survival with high and very high risk DRI organs
compared with LVC.
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Introduction
The volume–outcome relationship has been validated in surgery
across numerous specialties and high-risk procedures by a
growing body of literature over the past quarter of a century.1–4
However, as studies continue to demonstrate that high-volume
institutions deliver improved outcomes, particularly among high-
risk patient populations, the implication of these findings remains
controversial.5,6 This is because many volume–outcomes studies
are compromised by limited data, varying definitions of volume
groups and problematic statistical methodology.7,8 However,
nowhere is this debate more complex than in the field of liver
transplantation, where procedures are influenced not only by
recipient and transplantation centre factors, but also by a number
of donor variables.9–13
Unique to orthotopic liver transplantation, the ideal or refer-
ence donor is defined as less than 40 years of age, without signifi-
cant steatosis, chronic liver lesions or other transmissible diseases,
who deceased as a result of traumatic brain injury, is donating
after brain death and prior to haemodynamic instability.14 In the
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past, transplant surgeons were confronted with the challenge of
evaluating the donor by qualitatively comparing multiple risk
factors such as donor age, race, weight, cause of death, donations
after cardiac death (DCD), length of hospital stay before death,
use of vasopressors, cold ischaemia time and degree of steatosis.15
Feng et al. clarified the significance of donor variables by creating
the Donor Risk Index (DRI), which identified the following risk
factors for allograft failure: age (40 years old), split/partial
grafts, DCD, ethnicity (African-American), cause of death as a
result of a cerebrovascular accident (CVA), ‘other’ causes of death
and short stature.16
As annual procedure volume appears to positively impact
transplant outcomes, we aimed to determine whether this
volume–outcomes relationship existed among liver transplants at
high risk for allograft failure, as defined by DRI scores. Therefore,
using a risk-adjusted model accounting for donor, recipient,
regional and centre characteristics, we evaluated the combined
effect of annual procedure volume and DRI on allograft survival.
Methods
Database
Observations were queried from the Scientific Registry of Trans-
plant Recipients (SRTR), a nation-wide database that draws from
of the Organ Procurement and Transplantation Network
(OPTN). All adult recipients (18 years of age) of deceased donor
liver transplants between 1 January 2002 and 31 December 2008
were compiled. Procedures involving partial liver transplants
(reduced-liver, living donor and split-liver transplants) were
excluded from the analysis of differences in organ allocation
between these groups and the majority of patients with chronic
liver disease awaiting liver transplantation as previously
described.17
Volume groups
All observations were identified based on year and centre of trans-
plantation. Each institution was coded with encrypted hospital
identifiers, used to calculate centre-specific annual procedure
volumes. Centres were then ranked based on annual prolificacy.
Transplant centres with five or fewer cases in a year were excluded
to reduce confounding variables in our analysis. Based on this
order, centres were categorized into tertiles groups containing
even fractions of the dataset: low volume centres (LVC), middle
volume centres (MVC) and high volume centres (HVC). Because
centre-specific procedure volumes varied from year to year, centre
rank was re-calculated for each year studied as previously
described.3,18
DRI groups
Donor risk comparison groups were similarly stratified by quar-
tiles of the DRI spectrum, each containing an equal number of
observations: low risk (DRI  1.63), moderate risk (DRI = 1.64–
1.90), high risk (DRI = 1.91–2.26) and very high risk (DRI 
2.27).
Demographics and variables
Donor demographics included age, gender, ethnicity (Caucasian,
African American and all other minorities), cause of death
(anoxia, CVA, head trauma or other), DCD, cold ischaemia time
(in hours) and DRI. Recipient demographics included age, gender,
ethnicity, time spent on the waiting list, region, year of transplan-
tation and model for end-stage liver disease (MELD) score.
Nominal variables included gender, ethnicity, cause of death and
DCD status. Ordinal variables included year and region of trans-
plantation. Continuous variables included age, time spent on the
waitlist, cold ischaemia time, recipient MELD score and DRI.
MELD scores were calculated for each recipient based on the
United Network of Organ Sharing (UNOS) modification to the
formulary described in.19 DRI was calculated for each donor as
previously described.16
Analysis
Nominal and ordinal categorical variables were tested for statisti-
cal significance (P < 0.05) with Pearson’s c2-tests and the Mantel–
Haenszel c2-tests, respectively. Variation in central tendencies of
continuous variables between centre volume groups was evaluated
using Kruskal–Wallis non-parametric anova, because of non-
normal distribution. Univariate analysis of all categorical variables
was performed using the Log-Rank test of equality to evaluate for
significance as predictors of endpoints, defined as allograft failure.
Assessment results were visualized using Kaplan–Meier curves.
Variables included in the calculations of DRI16 and MELD,19 which
have already been shown to be significant, were excluded from
univariate analysis.
Four separate multivariate Cox proportional hazards regression
modelling were generated for each quartile of the DRI spectrum.20
These risk-adjusted models accounted for donor characteristics
(DRI), recipient characteristics (age, ethnicity and MELD), centre
volume groups (LVC, MVC and HVC) and location (Regions
1–11) shown to be significant on univariate analysis. Components
of the DRI and MELD score were omitted from the Cox regression
model to avoid over-adjustment. Each covariate was evaluated as
a predictor for allograft failure by maximum likelihood estimates
of hazard ratios (HR) and 95% confidence intervals (95% CI).
SAS version 9.2 (SAS Institute, Cary, NC) was used for all
statistical analysis. The present study was reviewed by the Univer-
sity of Massachusetts Medical School Institutional Review Board
(IRB) and deemed appropriate for exemption from IRB oversight
as no personal identifiers were used among datasets.
Results
Cohort description
In all, 31 587 OLT were queried. Between 92 and 102 transplant
centres actively contributed data to OPTN during the time period
448 HPB
HPB 2011, 13, 447–453 © 2011 International Hepato-Pancreato-Biliary Association
studied. Transplant centres were sorted into tertiles: LVC (33.64%
of cases; 46.06% of centres), MVC (33.93% of cases; 32.10% of
centres) and HVC (32.44% of cases; 21.84% of centres; P <
0.0001). Donor-risk comparison groups were stratified into quar-
tiles: low risk (DRI  1.63; n = 7922), moderate risk (1.63 < DRI
 1.90; n = 7918), high risk (1.90  DRI < 2.26; n = 7925) and
very high risk (DRI > 2.26; n = 7924). Regional trends suggest that
the largest contributions came from Region 3 (16.43% of cases),
whereas the smallest contributions came from Region 1 (2.79% of
cases), as described in Table 1.
Demographics
The majority of donors were male (59.54%) and Caucasians
(69.42%; P < 0.0001). The median donor age was 43 years and
15.72% were 60 years of age. The primary cause of death was
CVA (44.50%) and a minority were DCD donors (4.32%; P <
0.0001). The majority of recipients were also male (68.20%) and
Caucasian (73.45%). The median recipient age was 54 years with
a MELD score of 18.
Table 2 outlines the demographics of each tertile. The following
donor characteristics had statistically significant (P < 0.05) differ-
ences between tertiles: age, ethnicity, cause of death, DCD status
and DRI. The following recipient characteristics were also found
to be different: age, ethnicity, MELD score, time spent on the
waiting list and region. Evaluation of DRI groups showed that
higher volume groups utilizing higher median DRI allografts
(LVC: 1.82, MVC: 1.90, HVC: 1.97; P < 0.05), as depicted in Fig. 1.
In contrast, median MELD scores (LVC: 19.0, MVC: 19.0, HVC:
17.0; P < 0.05) and median time spent on the waiting list (LVC: 92
days, MVC: 79 days, HVC: 55 days; P < 0.05) were inversely pro-
portional to procedure volume.
Multivariate allograft survival outcomes
HVC achieved better overall risk-adjusted allograft survival out-
comes compared with LVC (HR: 0.90, 95%CI: 0.85–0.95) for all
patients who underwent liver transplantation. However, risk-
adjusted models showed that for low- and moderate-risk groups,
HVC did not confer significant graft survival benefits, as described
in Table 3, and shown in Fig. 2a–b, respectively. However, for high
and very high risk groups, HVC did significantly contribute to
graft survival (high risk: HR: 0.85, 95%CI: 0.76–0.96; very high
risk: HR: 0.88, 95%CI: 0.78–0.99), as described in Table 3, and
shown in Fig. 2c–d, respectively.
Discussion
The volume–outcome relationship in liver transplantation con-
tinues to be defined and its significance studied as a result of the
Table 1 Number of transplant centres per year and number of transplant cases per region per tertile group for all observations (n = 31 587)
Variables LVC
(n = 10 621)
MVC
(n = 10 713)
HVC
(n = 10 242)
Total
(n = 31 587)
2002 67 centres 18 centres 7 centres 92 centres
2003 39 centres 35 centres 20 centres 94 centres
2004 39 centres 32 centres 24 centres 95 centres
2005 41 centres 32 centres 24 centres 97 centres
2006 39 centres 33 centres 24 centres 96 centres
2007 40 centres 33 centres 24 centres 97 centres
2008 45 centres 33 centres 24 centres 102 centres
Region 1 880 cases 0 cases 0 cases 880 cases
Region 2 1837 cases 286 cases 1698 cases 3821 cases
Region 3 613 cases 1599 cases 2977 cases 5189 cases
Region 4 1284 cases 996 cases 849 cases 3129 cases
Region 5 2151 cases 575 cases 1598 cases 4324 cases
Region 6 403 cases 668 cases 0 cases 1071 cases
Region 7 905 cases 1565 cases 230 cases 2700 cases
Region 8 417 cases 1543 cases 0 cases 1960 cases
Region 9 0 cases 1971 cases 554 cases 2525 cases
Region 10 559 cases 458 cases 1954 cases 2971 cases
Region 11 1572 cases 1052 cases 382 cases 3006 cases
% of All Centers 46.06% 32.10% 21.84% 100%
% of All Cases 33.64% 33.93% 32.44% 100%
Median# Cases (SD) 31 cases (10.86) 64 cases (9.76) 102 cases (26.00) 197 cases
LVC, low volume centers; MVC, middle volume centres; HVC, high volume centres; %, per cent; #, number; SD, standard deviation.
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current era of quality, cost containment and health care reform. In
the present study, we have found that a centre volume benefit
exists at HVC and in a risk-stratified model, the largest benefit
appears to exist in the transplantation of the highest risk organs.
The current results are present in spite of minimal differences in
donor and recipient demographics. Risk-adjusted models showed
that for low- and moderate-risk groups, HVC did not confer
significant graft survival benefits. However, for high and very high
risk groups, HVC did contribute to improved graft survival of
12–15% compared with transplantation at LVC. While DRI
remains an important aspect of allograft survival prediction
models, further understanding in its use as a predictor for graft
failure is necessary.
Differences in centre volume were evident by groups, region as
well as year. Certain regions do have HVC in our cohort based on
tertiles for creating volume groups. Minor differences were seen in
donor and recipient demographics between volume groups. HVC
for instance, used organs with a higher DRI, but yet the median
MELD score of the recipient was lower. Further understanding in
Table 2 Donor and recipient demographics for all observations (n = 31 587)
Demographics LVC
(n = 10 621)
MVC
(n = 10 713)
HVC
(n = 10 242)
P-value
Recipient female 31.17% 32.19% 32.07% 0.223
Donor female 40.17% 40.38% 40.87% 0.569
Recipient ethnicity 0.003
Caucasian 72.31% 74.60% 73.50%
African American 9.18% 8.38% 8.41%
Other ethnicities 18.51% 17.02% 18.09%
Donor ethnicity <0.0001
Caucasian 69.03% 70.97% 68.28%
African American 14.62% 15.46% 15.51%
Other ethnicities 16.34% 13.57% 16.21%
Recipient age (18 years), Median 53 years 54 years 54 years <0.05
Donor age, median 41 years 43 years 45 years <0.05
40 years of age 51.29% 55.03% 58.37% <0.0001
60 years of age 12.39% 16.85% 18.02% <0.0001
Cold ischaemia time, median 7.0 h 7.0 h 7.0 h NA
Recipient wait time, median 92 days 79 days 55 days <0.05
Donor cause of death <0.0001
Anoxia 13.15% 14.22% 15.35%
CVA 43.36% 3.71% 46.53%
Head trauma 41.14% 38.72% 35.79%
Other 2.35% 3.35% 2.31%
DCD 3.51% 4.45% 5.04% <0.0001
Recipient MELD, Median (SD) 19.0 (9.10) 19.0 (8.84) 17.0 (8.65) <0.05
DRI, Median (SD) 1.82 (0.41) 1.90 (0.48) 1.97 (0.49) <0.05
HVC, high volume centres; MVC, middle volume centres; LVC, low volume centres; %, per cent; other ethnicities, Hispanics, Asians and ‘others’; CVA,
cerebrovascular accident or stroke; DCD, donation after cardiac death; DRI, donor risk index; SD, standard deviation; MELD, model for end-stage liver
disease; NA, not applicable.
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Figure 1 Box and whisker* plot of donor risk index (DRI) by trans-
plant centre volume, P < 0.0001. *Whiskers calculated as data 1.5
inter-quartile range
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Table 3 Risk-adjusted analysis of allograft failure risk among DRI quartiles
Centre volume groups Donor risk groups HR 95% CI P-value
LVC Low risk Reference – –
MVC 1.06 0.93, 1.20 0.41
HVC 0.99 0.86, 1.14 0.90
LVC Moderate risk Reference – –
MVC 1.04 0.92, 1.19 0.50
HVC 0.91 0.80, 1.04 0.16
LVC High risk Reference – –
MVC 0.90 0.80, 1.02 0.10
HVC 0.85 0.76, 0.96 0.007
LVC Very high risk Reference – –
MVC 1.01 0.89, 1.14 0.92
HVC 0.88 0.78, 0.99 0.03
LVC, low volume centres; MVC, middle volume centre; HVC, high volume centre; MELD, model for end-stage liver disease; DRI, donor risk index; HR,
hazard ratio; %, per cent; CI, confidence interval.
(a) (b)
(c) (d)
Figure 2 (a) Allograft survival by transplant Centre volume for low donor risk (DRI  1.63, n = 7922; P = 0.865). (b) Allograft survival by
transplant centre volume for moderate donor risk (1.63 < DRI  1.90, n = 7918; P = 0.718). (c) Allograft survival by transplant centre volume
for high donor risk (1.90 < DRI  2.26, n = 7925; P = 0.0006). (d) Allograft survival by transplant centre volume for very high donor risk
(DRI > 2.26, n = 7924; P = 0.0002)
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these practices is needed. Should centre volume be a component
in determining the true ‘risk index’ of use of an allograft?
In spite of its benefit as an addition to the donor pool, the use
of high-risk or marginal donor livers have brought about much
attention because of the potential for inferior outcomes. As no
defined criteria exists for expanded donor liver allografts, the DRI
as described by Feng, has gained acceptance in the liver transplant
community for quantification of donor risk and potential for
allograft failure.16,21,22 Use of these organs requires experience and
expertise and appropriate allocation for optimal use. Studies have
described its utility as well as its drawbacks with a comprehensive
risk assessment for all organs.21,23,24 Bashes et al. described accept-
able results with these high-risk organs by documenting reduced
mortality on the waiting list.25 We used the DRI to create quartile
gradients to assess if there is a volume impact on not only the use
of these organs, but also in the results after transplantation. In
these cohorts that were created based on quartiles of DRI, there
was no volume benefit at low- and medium-risk organs while a
significant advantage was noted in the higher risk organs. This is
the first report to describe a volume relationship with gradients of
DRI liver allografts.
The results of the present study are important because they
suggest a volume advantage with these high-risk allografts. While
further research is necessary to understand the implications of the
results, use of these organs clearly requires experience for optimal
results. Previous studies have shown conflicting data regarding the
role of volume with improved transplant outcomes.9,12,17 Based on
the data, it is unclear whether this is as a result of organ allocation,
recipient selection or post-transplant care. Identifying this level of
care and determining where the difference lies, if any, is imperative
to determine how we can improve outcomes overall and consider
the use of other high-risk organs such as hepatitis C positive livers,
older organs or donors with malignancy. As a result of the retro-
spective nature, large database used and inherent biases present in
the use of these organs, it is not possible to determine if there was
a reduction in waiting list mortality with the use of these organs at
HVC.
Several limitations must be considered. As this was a retro-
spective study, it has the associated constraints specific to the
variables collected in the SRTR database. While the database is
comprehensive and inclusive, it does not include significant
clinical variables that may be important for organ selection. For
example, data on steatosis or causes of allografts failure were not
available and thus could not be included in our analysis. Fur-
thermore, such standards may vary significantly from centre to
centre or between regions. We tried to control for this by exam-
ining the results within regions. All centres that performed
deceased donor liver transplantations and contributed data to
the SRTR database during the evaluated time period were uti-
lized in the present study. We excluded all centres that per-
formed less than five liver transplants per year to reduce
statistical variability and ensure the volume groups were appro-
priately represented.
A centre volume advantage exists in the use of increasingly
higher risk donor allografts. Based on these results, we have shown
that the potential for optimization for these high-risk organs may
exist in organ allocation, recipient selection or regional variability.
Further research and comparison in specific practices is impera-
tive to understand how best to optimize results and the use of
these allografts.
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